Toshihiro Tsuruda

Dr. Toshihiro Tsuruda

Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Miyazaki, Japan

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2008 in Circulation Research
Verified
Journal Article
Closed access
TTToshihiro Tsuruda
Toshihiro Tsuruda
JKJohji Kato
Johji Kato
KHKinta Hatakeyama
Kinta Hatakeyama
KKKazushi Kojima
Kazushi Kojima
MYMitsuhiro Yano
Mitsuhiro Yano
KKKazuo Kitamura
Kazuo Kitamura
Abdominal aortic aneurysm (AAA) is histologically characterized by medial degeneration and various degrees of chronic adventitial inflammation, although the mechanisms for progression of aneurysm are poorly understood. In the present study, we carried out histological study of AAA tissues of patients, and interventional animal and cell culture experiments to investigate a role of mast cells in the pathogenesis of AAA. The number of mast cells was found to increase in the outer media or adventitia of human AAA, showing a positive correlation between the cell number and the AAA diameter. Aneurysmal dilatation of the aorta was seen in the control (+/+) rats following periaortic application of calcium chloride (CaCl 2 ) treatment but not in the mast cell–deficient mutant Ws/Ws rats. The AAA formation was accompanied by accumulation of mast cells, T lymphocytes and by activated matrix metalloproteinase 9, reduced elastin levels and augmented angiogenesis in the aortic tissue, but these changes were much less in the Ws/Ws rats than in the controls. Similarly, mast cells were accumulated and activated at the adventitia of aneurysmal aorta in the apolipoprotein E–deficient mice. The pharmacological intervention with the tranilast, an inhibitor of mast cell degranulation, attenuated AAA development in these rodent models. In the cell culture experiment, a mast cell directly augmented matrix metalloproteinase 9 activity produced by the monocyte/macrophage. Collectively, these data suggest that adventitial mast cells play a critical role in the progression of AAA.

1 November 2006 in Hypertension
Verified
Journal Article
Closed access
HMHiroyuki Masuyama
Hiroyuki Masuyama
TTToshihiro Tsuruda
Toshihiro Tsuruda
JKJohji Kato
Johji Kato
TITakuroh Imamura
Takuroh Imamura
YAYujiro Asada
Yujiro Asada
TETanenao Eto
Tanenao Eto
It is unknown whether long-term pharmacological stimulation of soluble guanylate cyclase (sGC), elevating intracellular cGMP levels, has a beneficial effect on hypertension. The purpose of this study is to investigate the effects of BAY41-2272, an orally available sGC stimulator, on cardiovascular remodeling in hypertensive rats. Eight-week-old male Wistar rats with hypertension induced by angiotensin II infused subcutaneously at 250 ng/kg per minute were treated orally with a low ([L] 2 mg/kg per day) or high ([H] 10 mg/kg per day) dose of BAY41-2272 for 14 days. BAY41-2272-H partially suppressed the rise in blood pressure and reduced the heart weight (4.20±0.34 versus 3.68±0.20 mg/g; P <0.01), whereas BAY41-2272-L had no effect. However, both doses decreased the angiotensin II–induced left ventricular accumulation of collagen in the perivascular area (L, −20%, P <0.05; H, −30%, P <0.01) and myocardial interstitium (L, −21%, P <0.05; H, −38%, P <0.01), reducing the number of activated fibroblasts surrounding coronary arteries (L, −74%; H, −79%; P <0.05). BAY41-2272 downregulated the angiotensin II–induced left ventricular gene expression of type 1 collagen (L, −41%, P <0.05; H, −49%, P <0.01) and transforming growth factor-β1 (L, −49%, P <0.05; H, −65%, P <0.01). cGMP levels were elevated by BAY41-2272 not only in the left ventricle, but also in cultured cardiac fibroblasts, resulting in reduced thymidine incorporation into the cells. Thus, stimulation of sGC by BAY41-2272 attenuates fibrosis of the left ventricle in rats with angiotensin II–induced hypertension partly in a pressure-independent manner, suggesting an important role for sGC generating cGMP in inhibiting cardiovascular remodeling.

1 June 2012 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
TTToshihiro Tsuruda
Toshihiro Tsuruda
KHKinta Hatakeyama
Kinta Hatakeyama
SNShigeki Nagamachi
Shigeki Nagamachi
YSYoko Sekita
Yoko Sekita
SSSumiharu Sakamoto
Sumiharu Sakamoto
KKKazuo Kitamura
Kazuo Kitamura
Objective—: The mechanisms underlying abdominal aortic aneurysm development remain unknown. We hypothesized that acceleration of glucose metabolism with the upregulation of glucose transporters is associated with abdominal aortic aneurysm development. Methods and Results—: Enhanced accumulation of the modified glucose analogue 18 fluoro-deoxyglucose by positron emission tomography imaging in the human abdominal aortic aneurysm was associated with protein expressions of glucose transporters-1 and -3, assessed by Western blot. The magnitude of glucose transporter-3 expression was correlated with zymographic matrix metalloproteinase-9 activity. Intraperitoneal administration of glycolysis inhibitor with 2-deoxyglucose significantly attenuated the dilatation of abdominal aorta induced by periaortic application of CaCl 2 in C57BL/6J male mice or reduced the aneurysmal formation in angiotensin II-infused apolipoprotein E knockout male mice. In monocytic cell line induced by phorbol 12-myristate 13-acetate or ex vivo culture obtained from human aneurysmal tissues, 2-deoxyglucose abrogated the matrix metalloproteinase-9 activity and interleukin-6 expression in these cells/tissues. Moreover, 2-deoxyglucose attenuated the survival/proliferation of monocytes and the adherence of them to vascular endothelial cells. Conclusion—: This study suggests that the enhanced glycolytic activity in aortic wall contributes to the pathogenesis of aneurysm development. In addition, pharmacological intervention in glycolytic activity might be a potential therapeutic target for the disorder.

1 January 2019 in Peptides
Verified
Journal Article
Closed access
TTToshihiro Tsuruda
Toshihiro Tsuruda
Johji KatoJohji Kato
Johji Kato
KKKenji Kuwasako
Kenji Kuwasako
KKKazuo Kitamura
Kazuo Kitamura

1 February 2021 in Internal Medicine
Verified
Journal Article
Open access
PDF file
TTToshihiro Tsuruda
Toshihiro Tsuruda
NYNaoki Yoshikawa
Naoki Yoshikawa
MKMotoaki Kai
Motoaki Kai
MYMasashi Yamaguchi
Masashi Yamaguchi
RTReiko Toida
Reiko Toida
RIRyuji Ikeda
Ryuji Ikeda
We herein report the cytokine expression at different stages for three patients who developed cardiac complications after immune checkpoint inhibitor (ICI) therapy. Patient 1 with biopsy-proven myocarditis showed increased levels of interleukin (IL)-8, monocyte chemotactic and activating factor, and granulocyte macrophage colony-stimulating factor (GM-CSF) when he developed Takotsubo cardiomyopathy. Patient 2 with subclinical myocarditis showed predominant activation of IL-8 during the progressive clinical course. Patient 3 with cytokine-releasing syndrome showed substantial activations of IL-6, IL-8, GM-CSF, and interferon-γ. Our data suggest the development of unique cytokine activation in individual patients with cardiac complications after ICI therapy.

1 December 2004 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
TTToshihiro Tsuruda
Toshihiro Tsuruda
JKJohji Kato
Johji Kato
YCYuan-Ning Cao
Yuan-Ning Cao
KHKinta Hatakeyama
Kinta Hatakeyama
HMHiroyuki Masuyama
Hiroyuki Masuyama
TETanenao Eto
Tanenao Eto